<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209816</url>
  </required_header>
  <id_info>
    <org_study_id>HUS/53/2017</org_study_id>
    <nct_id>NCT04209816</nct_id>
  </id_info>
  <brief_title>Genetic Pathways Leading to Fatty Liver and Atherogenic Dyslipidemia</brief_title>
  <acronym>VARKIN</acronym>
  <official_title>Genetic Regulation of Lipid Pathways Contributing to Non-alcoholic Fatty Liver and Atherogenic Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Marja-Riitta Taskinen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Göteborg University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are:

        1. To investigate if carriers of apolipoprotein (apo) CIII loss-of-function (LOF) mutations
           produce less apo-CIII that results in reduction of large very low-density lipoprotein
           (VLDL) particle secretion as compared to non-carriers of these variants and compare the
           results with carriers of apo-CIII gain-of-function (GOF) to elucidate the role of
           apo-CIII in hepatic lipid metabolism.

        2. To study if carriers of the TM6SF2 E167K and PNLPLA3 I148M mutations produce less large
           VLDL particles to transport fat out of the liver as compared to non-carriers.

        3. To test whether the specific mutations in the apo-CIII, TM6SF2 and PNLPLA3 genes are
           reflected in changes of liver de novo lipogenesis (DNL), liver fat, Homeostatic Model
           Assessment for Insulin Resistance (HOMA-IR), plasma lipid and apolipoprotein kinetics
           and fasting concentrations in carriers of the TM6SF2 E167K and PNLPLA3 I148M mutations
           as compared to non-carriers.

        4. To study the effects of APOE, angiopoietin (ANGPTL3 and ANGPTL8) or endothelial lipase
           (LIPG) genotypes on liver fat metabolism, lipid and apolipoprotein metabolism and lipid
           phenotypes.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">December 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in the rate of production of VLDL Apo B</measure>
    <time_frame>Baseline</time_frame>
    <description>Production rate, mg/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in the rate of production of VLDL Triglycerides</measure>
    <time_frame>Baseline</time_frame>
    <description>Production rate, mg/kg/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in the rate of production of VLDL ApoC-III and apoE</measure>
    <time_frame>Baseline</time_frame>
    <description>Production rate, mg/kg/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in the Fractional Catabolic Rate of VLDL Apo B</measure>
    <time_frame>Baseline</time_frame>
    <description>Rate of disappearance, pools/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in the Fractional Catabolic Rate of VLDL Triglycerides</measure>
    <time_frame>Baseline</time_frame>
    <description>Rate of disappearance, pools/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in the Fractional Catabolic Rate of VLDL ApoC-III and apoE</measure>
    <time_frame>Baseline</time_frame>
    <description>Rate of disappearance, pools/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in de novo lipogenesis</measure>
    <time_frame>Baseline</time_frame>
    <description>Measure of newly synthesized triglycerides in VLDL, μmol/l</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in liver fat</measure>
    <time_frame>Baseline</time_frame>
    <description>Percentage of liver fat measured with magnetic resonance spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in atherogenic dyslipidemia</measure>
    <time_frame>Baseline</time_frame>
    <description>Remnant lipoproteins and lipoprotein fraction composition, mg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in insulin resistance</measure>
    <time_frame>Baseline</time_frame>
    <description>Calculated Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in apoprotein A concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>ApoA, mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in apoprotein B concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>ApoB, mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in apoprotein C concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>ApoC, mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in apoprotein E concentration</measure>
    <time_frame>Baseline</time_frame>
    <description>ApoE, mg/dl</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in the rate of production and Fractional Catabolic Rate of intermediate-density Apo B</measure>
    <time_frame>Baseline</time_frame>
    <description>Rate of turnover, pools/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in the rate of production and Fractional Catabolic Rate of low-density lipoprotein Apo B</measure>
    <time_frame>Baseline</time_frame>
    <description>Rate of turnover, pools/day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipolytic activity</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured lipoprotein lipase activity, mU/ml</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic lipase activity</measure>
    <time_frame>Baseline</time_frame>
    <description>Measured hepatic lipase activity, mU/ml</description>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-alcoholic Fatty Liver</condition>
  <condition>Atherogenic Dyslipidemia</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>ApoC-III LOF</arm_group_label>
    <description>Carriers of apo-CIII loss-of-function mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ApoC-III GOF</arm_group_label>
    <description>Carriers of apo-CIII gain-of-function mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TM6SF2-KK</arm_group_label>
    <description>Carriers of TM6SF2 E167K mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PNLPLA3-MM</arm_group_label>
    <description>Carriers of PNLPLA3 I148M mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>No ApoC-III, TM6SF2 E167K or PNLPLA3 I148M mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ApoE variants</arm_group_label>
    <description>Carriers of E2/2, E3/3 or E4/4 mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LIPG</arm_group_label>
    <description>LIPG gene LOF or GOF variant carriers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ANGPTL3 or ANGPTL8</arm_group_label>
    <description>ANGPTL3 and ANGPTL8 gene LOF or GOF variant carriers</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lipoprotein kinetics</intervention_name>
    <description>Lipoprotein kinetic apply protocol that endogenously label proteins and fatty acids with stable isotope-labeled amino acid and glycerol tracers. De novo lipogenesis is measured after ingestion of deuterated water to measure newly formed fatty acids in VLDL. Liver fat is measured with magnetic resonance spectroscopy and lipolytic enzymes with heparin test.</description>
    <arm_group_label>ApoC-III GOF</arm_group_label>
    <arm_group_label>ApoC-III LOF</arm_group_label>
    <arm_group_label>ApoE variants</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>LIPG</arm_group_label>
    <arm_group_label>PNLPLA3-MM</arm_group_label>
    <arm_group_label>TM6SF2-KK</arm_group_label>
    <other_name>Measurement of de novo lipogenesis</other_name>
    <other_name>Measurement of lipolytic activity</other_name>
    <other_name>Measurement of liver fat</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory outpatients who are recruited from our previous study investigating familial
        dyslipidemia where exome sequency has been performed to explore genes involved in lipid
        metabolism (HUCH Ethics Committee, Department of Medicine: 108/1996, follow-up studies Dnro
        170/E5/02, Drno 215/13/03/01/2009, Drno 144/13/03/01/2011 and HUCH Coordinating Ethics
        Committee Drno 184/13/03/00/2012, and Drno 183/13/03/00/2012). All subjects who have given
        oral consent that they can be informed about new studies focused on lipid metabolism will
        be contacted. To recruite the subjects we will use the invitation letter and follow up all
        the policy as stipulated in the Finnish biobank law (688/2012)
        (http//nationalbiobanks.fi/index.php./studies2/7-finrisk).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persons who have provided written consent

          -  apo-CIII loss-of-function mutation (heterozygous) or apo-CIII gain-of-function
             mutations (heterozygous) or TM6SF2 E167K mutation (homozygous) or PNLPLA3 I148M or
             apoE or LIPG or ANGPTL3 or ANGPTL8 LOF and GOF variants. Control group without any of
             known risk variants in these genes.

          -  Hemoglobin A1c &lt; 6.5%

          -  Body mass index between 18.5 and 40 kg/m²

          -  Estimated glomerular filtration rate &gt; 60 ml/min/1.73 m² at inclusion

        Exclusion Criteria:

          -  Patients with Type 1 and 2 diabetes, BMI &gt; 40 kg/m2,

          -  ApoE2/2 phenotype, thyrotropin concentration outside normal range,

          -  Lipid-lowering drugs

          -  Blood pressure &gt;160 mmHg systolic and/or &gt; 105 diastolic mmHg

          -  Liver failure or abnormal liver function tests &gt;3 x upper limit of normal

          -  Intestinal disease

          -  Pregnancy, breastfeeding

          -  Patients with volume depletion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>RPU Clinical and Molecular Metabolism, Biomedicum</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wallenberg Laboratory</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 19, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>December 20, 2019</last_update_submitted>
  <last_update_submitted_qc>December 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Marja-Riitta Taskinen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Non-alcoholic Fatty Liver</keyword>
  <keyword>Apoproteins</keyword>
  <keyword>Genetic variants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

